Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 8/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PFKFB4 | Q16877 | 3/20 | 0.41 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3939520 | 0.84 | ROCK1 (1.00) | ROCK1KDM4ECYP2A6NPSR1L3MBTL1 | |
| SCHEMBL10745872 | 0.80 | ROCK1 (0.48) | ROCK1KDM4EIDO1L3MBTL1PFKFB4 | |
| SCHEMBL2824154 | 0.80 | ROCK1 (0.56) | ROCK1PFKFB4PFKFB3MAPT | |
| SCHEMBL2826864 | 0.80 | ROCK1 (0.56) | ROCK1KDM4ENPSR1L3MBTL1PFKFB4 | |
| SCHEMBL11560607 | 0.80 | ROCK1 (0.48) | ROCK1KDM4EIDO1CYP2A6MAPT | |
| SCHEMBL4262796 | 0.78 | ROCK1 (0.49) | ROCK1L3MBTL1 | |
| SCHEMBL11531784 | 0.77 | ROCK1 (0.46) | ROCK1KDM4EIDO1CYP2A6MAPT | |
| Hydrochloric Acid SCHEMBL27553020 | 0.77 | ROCK1 (0.46) | ROCK1KDM4EIDO1CYP2A6 | |
| SCHEMBL14311003 | 0.77 | ROCK1 (0.76) | ROCK1CYP2A6NPSR1L3MBTL1MAPT | |
| SCHEMBL5094432 | 0.77 | ROCK1 (0.76) | ROCK1KDM4ECYP2A6NPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7126012-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-24 | — | — | US | disclosed |
| US-7115752-B2 | Substituted cyclic compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-03 | — | — | US | disclosed |
| US-20050124682-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-06-09 | — | — | US | disclosed |
| US-6872851-B1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20050059729-A1 | Substituted cyclic compounds | LESIEUR DANIEL (FR) | 2005-03-17 | — | — | US | disclosed |
| EP-1077927-A1 | NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058495-A1 | NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 1999-11-18 | — | — | WO | disclosed |
| US-4137414-A | NEUROLEPTICS, BACTERICIDES | G. D. SEARLE & CO. (US) | 1979-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059729-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | ROCK1 1089/4885KDM4E 1740/4885IDO1 2561/4885 |
| US-20050124682-A1 | Substituted cyclic compounds | CCNY, CCNT2, TECR | ROCK1 1089/4885KDM4E 1740/4885IDO1 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.